These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 20176894)

  • 21. Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811.
    Goto K; Watashi K; Murata T; Hishiki T; Hijikata M; Shimotohno K
    Biochem Biophys Res Commun; 2006 May; 343(3):879-84. PubMed ID: 16564500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
    Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dominant negative effect of wild-type NS5A on NS5A-adapted subgenomic hepatitis C virus RNA replicon.
    Graziani R; Paonessa G
    J Gen Virol; 2004 Jul; 85(Pt 7):1867-1875. PubMed ID: 15218171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796.
    Howe AY; Cheng H; Johann S; Mullen S; Chunduru SK; Young DC; Bard J; Chopra R; Krishnamurthy G; Mansour T; O'Connell J
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3327-38. PubMed ID: 18559648
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Ng TI; Krishnan P; Pilot-Matias T; Kati W; Schnell G; Beyer J; Reisch T; Lu L; Dekhtyar T; Irvin M; Tripathi R; Maring C; Randolph JT; Wagner R; Collins C
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppression of viral RNA binding and the assembly of infectious hepatitis C virus particles in vitro by cyclophilin inhibitors.
    Nag A; Robotham JM; Tang H
    J Virol; 2012 Dec; 86(23):12616-24. PubMed ID: 22973029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance studies of a dithiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems.
    Lin HM; Wang JC; Hu HS; Wu PS; Wang WH; Wu SY; Yang CC; Yeh TK; Hsu TA; Jiaang WT; Chao YS; Chern JH; Yueh A
    Antimicrob Agents Chemother; 2013 Feb; 57(2):723-33. PubMed ID: 23165461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo.
    Inoue K; Umehara T; Ruegg UT; Yasui F; Watanabe T; Yasuda H; Dumont JM; Scalfaro P; Yoshiba M; Kohara M
    Hepatology; 2007 Apr; 45(4):921-8. PubMed ID: 17393519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories.
    Chatterji U; Bobardt M; Tai A; Wood M; Gallay PA
    Antimicrob Agents Chemother; 2015 May; 59(5):2496-507. PubMed ID: 25666154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors.
    Yang W; Zhao Y; Fabrycki J; Hou X; Nie X; Sanchez A; Phadke A; Deshpande M; Agarwal A; Huang M
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2043-52. PubMed ID: 18411324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutations in HCV non-structural genes do not contribute to resistance to nitazoxanide in replicon-containing cells.
    Yon C; Viswanathan P; Rossignol JF; Korba B
    Antiviral Res; 2011 Sep; 91(3):233-40. PubMed ID: 21703309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of AlphaLISA technology to detect interaction between hepatitis C virus-encoded NS5A and cyclophilin A.
    Waller H; Chatterji U; Gallay P; Parkinson T; Targett-Adams P
    J Virol Methods; 2010 May; 165(2):202-10. PubMed ID: 20132841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants.
    Gottwein JM; Pham LV; Mikkelsen LS; Ghanem L; Ramirez S; Scheel TKH; Carlsen THR; Bukh J
    Gastroenterology; 2018 Apr; 154(5):1435-1448. PubMed ID: 29274866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
    Flint M; Mullen S; Deatly AM; Chen W; Miller LZ; Ralston R; Broom C; Emini EA; Howe AY
    Antimicrob Agents Chemother; 2009 Feb; 53(2):401-11. PubMed ID: 18936191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HCV1b genome evolution under selective pressure of the cyclophilin inhibitor alisporivir during the DEB-025-HCV-203 phase II clinical trial.
    Cuypers L; Snoeck J; Kerremans L; Libin P; Crabbé R; Van Dooren S; Vuagniaux G; Vandamme AM
    Infect Genet Evol; 2016 Oct; 44():169-181. PubMed ID: 27374748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclophilin inhibitors for hepatitis C therapy.
    Membreno FE; Espinales JC; Lawitz EJ
    Clin Liver Dis; 2013 Feb; 17(1):129-39. PubMed ID: 23177289
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase.
    Kukolj G; McGibbon GA; McKercher G; Marquis M; Lefèbvre S; Thauvette L; Gauthier J; Goulet S; Poupart MA; Beaulieu PL
    J Biol Chem; 2005 Nov; 280(47):39260-7. PubMed ID: 16188890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple cyclophilins involved in different cellular pathways mediate HCV replication.
    Gaither LA; Borawski J; Anderson LJ; Balabanis KA; Devay P; Joberty G; Rau C; Schirle M; Bouwmeester T; Mickanin C; Zhao S; Vickers C; Lee L; Deng G; Baryza J; Fujimoto RA; Lin K; Compton T; Wiedmann B
    Virology; 2010 Feb; 397(1):43-55. PubMed ID: 19932913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of interaction between hepatitis C virus NS5A and NS5B on hepatitis C virus RNA replication with the hepatitis C virus replicon.
    Shimakami T; Hijikata M; Luo H; Ma YY; Kaneko S; Shimotohno K; Murakami S
    J Virol; 2004 Mar; 78(6):2738-48. PubMed ID: 14990694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479.
    Ali S; Leveque V; Le Pogam S; Ma H; Philipp F; Inocencio N; Smith M; Alker A; Kang H; Najera I; Klumpp K; Symons J; Cammack N; Jiang WR
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4356-69. PubMed ID: 18838588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.